Asplenia
6
4
4
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
17%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients
Development of an Italian Questionnaire for Splenectomized Patients Using a Delphi Consensus Method
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
Evaluation of the Effectiveness of an Educational Intervention in Splenectomized Patients
B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals